Surotomycin versus vancomycin forClostridium difficileinfection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial

Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial

(2016) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of Surotomycin on Clostridium difficile Viability and Toxin ProductionIn Vitro

(2015) Laurent Bouillaut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Surotomycin Demonstrates LowIn VitroFrequency of Resistance and Rapid Bactericidal Activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium

(2014) Carmela T. M. Mascio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

(2014) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection

(2014) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens

(2012) D. R. Snydman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroandIn VivoCharacterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficile

(2012) Carmela T. M. Mascio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain

(2012) Laurica A. Petrella et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

In VitroActivities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health Care–AssociatedClostridium difficileInfection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study

(2009) Denise Gravel et al.   CLINICAL INFECTIOUS DISEASES

Meta-analysis to assess risk factors for recurrent Clostridium difficile infection

(2008) K.W. Garey et al.   JOURNAL OF HOSPITAL INFECTION